A structure-based drug design approach for the identification of novel selective Cyclooxygenase-2 inhibitors using resveratrol analogues as lead molecules by Caruana, Clarissa & Shoemake, Claire
www.bmjournal.in BM/Vol.6/ October 2015/bm- 1319250115 
ISSN 0976 – 9080 
BIOMIRROR 
                                                                                                                                                 An Open Access Journal 
A Structure-Based Drug Design Approach for the Identification of Novel 
Selective Cyclooxygenase-2 Inhibitors using Resveratrol Analogues as Lead 
Molecules 
 
a Clarissa Caruana *,  
a Claire Shoemake 
 
a 
Department of Pharmacy, Faculty of Medicine and Surgery, University of Malta, MALTA. 
 
100 BIOMIRROR                                    ISSN 0976 – 9080 BM, an open access journal                              Volume 6(10) :100-113(2015)  
 
ARTICLE INFO 
 
Received 13 September 2015 
Revised 20 September 2015 
Accepted 24 September 2015 
Available Online 04 October 2015 
 
Keywords: 
 
Cyclooxygenase-2,  
Resveratrol analogues,  
Celecoxib,  
Drug design 
 
 
 
 
 
 
ABSTRACT 
 
Therapeutic areas for selective cyclooxygenase-2 inhibitors include 
inflammatory conditions and cancer. A study has demonstrated that 
hydroxylated analogues of resveratrol, which is found in red wine, 
inhibit cyclooxygenase-2 selectively. This study aimed to design in 
silico novel selective cyclooxygenase-2 inhibitors using two of these 
resveratrol analogues, namely 3,3’,4’,5-tetrahydroxystilbene and 
3,3’,4,4’,5,5’-hexahydroxystilbene, as molecular templates. Two 
hundred molecules were generated de novo from each of these 
analogues. The binding affinities (pKd) of the novel molecules ranged 
from 9.70 to 10.00.  In total, 10% of the molecules were compliant 
with Lipinski Rules, and hence, were orally bioavailable. The Lipinski 
Rules compliant molecules with high affinities can be included in 
libraries of selective cyclooxygenase-2 inhibitors to be used in high-
throughput screening. 
 
Introduction: 
Cyclooxygenase (COX) isoenzymes catalyse the 
synthesis of prostanoids, namely prostaglandins, prostacyclin 
and thromboxane A2
1. COX-1 is constitutively expressed in 
most tissues of the body1 and is mainly responsible for the 
production of prostaglandins involved in homeostatic 
processes, including the conservation of gastric mucosal 
integrity and renal function2. COX-2 is mostly induced and is 
the source of prostaglandins which promote fever, pain and 
inflammation1.  
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COX-2 is also over-expressed in several tumours 
and has oncogenic effects3. It is associated with tumour 
promotion, angiogenesis, metastasis and inhibition of 
apoptosis4. Selective inhibitors of COX-2 are 
chemopreventive, and they also sensitise tumour cells to the 
effects of chemotherapy or radiotherapy when used as 
adjuvant agents3. However, the duration of intake of COX-2 
inhibitors is limited by the increased risk of cardiovascular 
thrombotic events, including myocardial infarction5. 
Therefore, COX-2 is a viable target for the design of selective  
 
COX-2 inhibitors having potential utility in the 
management of cancer and with an improved cardiovascular 
safety profile. 
Products from natural sources can be used as lead 
compounds in the process of drug design. A study by Murias 
et al.6 showed that hydroxylated analogues of resveratrol 
inhibit COX-2 selectively. Two of these analogues, namely 
3,3’,4’,5-tetrahydroxystilbene and 3,3’,4,4’,5,5’-
hexahydroxystilbene, are highly selective, with the latter 
being even more selective than the marketed selective COX-2 
inhibitor, celecoxib6. This study aimed to design and optimise 
a series of selective COX-2 inhibitors which possess a high 
affinity for COX-2 and oral bioavailability, using 3,3’,4’,5-
tetrahydroxystilbene and 3,3’,4,4’,5,5’-hexahydroxystilbene 
as molecular templates.  
 
Method & Materials: 
X-ray crystallographic deposition 3LN17 (Fig.1) 
was selected from the Protein Data Bank9. The deposition 
described the bound co-ordinates of the selective COX-2 
inhibitor celecoxib with COX-2. COX-2 was crystallised as a 
tetramer, with each of the four chains bound to celecoxib. 
The 3D co-ordinates were read into Sybyl®-X v.1.210and the 
deposition was simplified in order to reduce computer 
intensiveness in subsequent stages of the design process. 
Simplification was carried out via the removal of three holo-
chains, namely A, C and D. This was followed by the 
removal of moieties, which were not considered critical to 
binding, from the remaining chain B. Water molecules were 
also removed. The result was a monomer of COX-2, chain B, 
bound to celecoxib (Fig. 2).  
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Figure 1. X-ray crystallographic deposition 3LN1, generated 
using Accelrys Discovery Studio® v.4.08 
 
 
 
Figure 2. Celecoxib bound in the binding pocket of chain B, 
generated using Accelrys Discovery Studio® v.4.08 
 
 
 
Using Sybyl®-X v.1.210, celecoxib was extracted with 
preserved co-ordinates from the ligand binding pocket (LBP) 
of COX-2, and saved in MOL2 format (Fig.3). The resultant 
apo-monomer was saved in PDB format. Both celecoxib and 
chain B were read into X-Score® v.1.311and the Ligand 
Binding Affinity (LBA) (pKd) of celecoxib for COX-2 was 
calculated.  
 
Figure 3. Celecoxib extracted from the COX-2 LBP, 
generated using Accelrys Discovery Studio® v.4.08 
 
 
 
 
 
         The resveratrol analogues 3,3’,4’,5-tetrahydroxystilbene 
and 3,3’,4,4’,5,5’-hexahydroxystilbene (Figs. 4-5) were 
sketched in Sybyl®-X v.1.210and saved in MOL2 format.  
 
Figure 4. Structure of 3,3’,4’,5-
tetrahydroxystilbene,generated using Accelrys Discovery 
Studio® v.4.08 
 
 
 
Figure 5. Structure of 3,3’,4,4’,5,5’-
hexahydroxystilbene,generated using Accelrys Discovery 
Studio® v.4.08 
 
 
 
The resveratrol analogues were docked into the 
COX-2 LBP via Sybyl®-X v.1.210 using celecoxib in MOL2 
format as a template. Conformational analysis was carried out 
and the twenty binding conformers having the highest 
affinities for COX-2 were selected. Each conformer was 
exported in MOL2 format.  
Each binding conformer was read into X-Score® 
v.1.311 and its LBA (pKd) for COX-2 was quantified. The 
Ligand Binding Energy (LBE) (kcal mol-1) of each conformer 
was calculated using Sybyl®-X v.1.210. Graphs of LBA (pKd) 
and LBE (kcal mol-1) against binding conformer number 
were plotted for each resveratrol analogue. The conformer 
exhibiting the optimal combination of high LBA (pKd) and 
low LBE (kcal mol-1) was identified from the graph for each 
analogue. These two conformers were imported in Sybyl®-X 
v.1.210 for editing. Editing involved the removal of a benzene 
ring from each conformer, followed by the addition of a 
growing site via an atom type modification from a carbon 
atom to H.spc atom. This resulted in the formation of a seed 
structure, for each of the two optimal binding conformers 
(Figs 6-7), which was saved in MOL2 format.  
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Figure 6. Structure of seed derived from 3,3’,4’,5-
tetrahydroxystilbene, generated using Accelrys Discovery 
Studio® v.4.08 
 
 
Figure7. Structure of seed derived from 3,3’,4,4’,5,5’-
hexahydroxystilbene,generated using Accelrys Discovery 
Studio® v.4.08 
 
LigBuilder® v.1.212was used for the in silico 
construction of novel molecules. LigBuilder® v.1.212 
consisted of three modules, namely the POCKET module 
which analysed the LBP, the GROW module via which 
molecular growth occurred at the designated growing site, 
and the PROCESS module which generated the novel 
molecules. 
Firstly, the parameter file for the POCKET module 
was edited, selecting Chain B as the receptor and the 
extracted celecoxib as the ligand. The POCKET module was 
then allowed to run. The parameter file for the GROW 
module was then edited. Each seed structure was used as an 
input file in the GROW module. The output files of the 
POCKET module, namely the atom file, which consisted of 
the atoms making up the LBP, and the grid file, which 
comprised the grids within the LBP, were also selected as 
input files. The GROW module was run twice, one time for 
each seed structure.  
The ligand_collection_file, which resulted from the 
GROW module, was subsequently used in the PROCESS 
module. Two hundred novel molecules and an index file were 
created for each seed structure. The index file contained the 
family number, molecular formula, molecular weight, 
calculated logP and binding score (pKd) of each novel 
molecule.  
The novel molecules were filtered according to 
LBA and Lipinski Rules13compliance criteria. The molecules 
which satisfied the criteria in terms of molecular weight and 
logP had their numbers of hydrogen bond acceptors and 
hydrogen bond donors calculated in Accelrys Draw®v.4.114 to 
establish whether they complied with all of the Lipinski 
Rules13 criteria.  
 
Results: 
The LBA (pKd) of celecoxib was 7.40. This was 
used as a baseline against which the affinities (pKd) of the 
novel generated molecules were subsequently compared.  
The twenty binding conformers of 3,3’,4’,5-
tetrahydroxystilbene  and 3,3’,4,4’,5,5’-hexahydroxystilbene 
are shown superimposed onto each other in Figures 8 and 9, 
respectively. The graph of LBA (pKd) and LBE (kcal mol-1) 
against conformer number plotted for 3,3’,4’,5-
tetrahydroxystilbene is displayed in Figure 10 and that 
plotted for 3,3’,4,4’,5,5’-hexahydroxystilbene is displayed in 
Figure 11. For each resveratrol analogue, the best binding 
conformer identified from the graph was the one having the 
highest peak distance between LBA (pKd) and LBE (kcal 
mol-1), on the premise that this would combine high affinity 
with molecular stability. 
 
Figure 8. Binding conformers of 3,3’,4’,5-
tetrahydroxystilbene, generated using Accelrys Discovery 
Studio® v.4.08. The optimal conformer is highlighted in 
yellow
 
 
Figure 9.  Binding conformers of 3,3’,4,4’,5,5’-
hexahydroxystilbene, generated using Accelrys Discovery 
Studio® v.4.08. The optimal conformer is highlighted in 
yellow 
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Figure 10. Graph of LBA (pKd) and LBE (kcal mol-1) against conformer number for 3,3’,4’,5-tetrahydroxystilbene. The best 
conformer is encircled in green 
 
 
 
 
 
 
 
Figure 11. Graph of LBA (pKd) and LBE (kcal mol-1) against conformer number for 3,3’,4,4’,5,5’-hexahydroxystilbene. The 
best conformer is encircled in green. 
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When the POCKET module within LigBuilder® v.1.212 was 
run, a key_site.pdb file and a pharmacophore.pdb file were 
derived. The key_site.pdb file represented the key binding 
sites (Fig.12) within the LBP of COX-2, whilst the 
pharmacophore.pdb file represented the pharmacophore 
model (Fig. 13) for COX-2. 
 
Figure 12. Key interaction sites within COX-2, generated 
using Accelrys Discovery Studio® v.4.08. Hydrogen bond 
donor grids are displayed in blue, hydrogen bond acceptor 
grids in red and hydrophobic grids in grey 
 
 
 
Two hundred molecules were created de novo for 
each resveratrol analogue. The LBAs (pKd) of the novel 
molecules generated from the seed structure of 3,3’,4’,5-
tetrahydroxystilbene ranged from 9.73 to 10.00, whilst the 
affinities (pKd) of those derived from the seed structure of 
3,3’,4,4’,5,5’-hexahydroxystilbene ranged from 9.70 to 
10.00, higher than that of celecoxib (pKd 7.40). 
Figure 13. Pharmacophore model for COX-2, generated 
using Accelrys Discovery Studio® v.4.08. Hydrogen bond 
donor grids are displayed in blue, hydrogen bond acceptor 
grids in red and hydrophobic grids in grey 
 
 
 
Lipinski Rules13 state that drugs may be poorly 
absorbed by the body if the molecular weight is greater than 
500, the logP is greater than 5, there are more than 10 
hydrogen bond acceptors and there are more than 5 hydrogen 
bond donors. Twenty out of the two hundred novel molecules 
generated from the seed of 3,3’,4’,5-tetrahydroxystilbene, as 
well as twenty out of the two hundred molecules generated 
from the seed of 3,3’,4,4’,5,5’-hexahydroxystilbene, were 
compliant with Lipinski Rules13. The structures and 
properties of the Lipinski Rules13 compliant molecules which 
have the highest LBA (pKd) values from their respective 
families are presented in Tables 1 and 2. 
 
Table 1. Properties and structures of the Lipinski rules compliant molecules, having the highest pKd values, generated from the 
seed structure of 3,3’,4’,5-tetrahydroxystilbene. The structures were generated using Accelrys Draw® v.4.114 
 
Family 
Number 
LBA 
(pKd) 
Molecular 
Weight 
LogP Number of 
Hydrogen 
Bond 
Acceptors 
Number of 
Hydrogen 
Bond Donors 
Structure 
2 9.97 335 4.65 4 3 
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3 10.00 394 4.96 
 
5 4 
 
4 9.99 372 5.00 4 3 
 
7 9.86 457 4.45 6 5 
 
10 9.85 374 4.58 3 3 
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Table 2. Properties and structures of the Lipinski rules compliant molecules, having the highest pKd values, generated from the 
seed structure of 3,3’,4,4’,5,5’-hexahydroxystilbene. The structures were generated using Accelrys Draw® v.4.114 
 
Family 
Number 
LBA (pKd) Molecular 
Weight 
LogP Number of 
Hydrogen 
Bond 
Acceptors 
Number of 
Hydrogen 
Bond Donors 
Structure 
1 9.84 340 4.95 4 4 
 
2 9.98 324 4.92 4 3 
 
4 9.74 336 4.74 4 3 
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5 9.89 424 5.00 5 4 
 
6 9.85 386 4.94 5 4 
 
8 9.97 366 4.92 5 4 
 
9 9.82 308 4.56 4 3 
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9 9.82 310 4.82 4 3 
 
11 9.87 326 4.98 4 3 
 
 
 
 
Discussion: 
The pharmacophores of the families which 
comprised Lipinski Rules13 compliant molecules, along with 
the binding affinities (pKd) of the molecules, were analysed 
to determine whether the addition or removal of a moiety at a 
particular locus resulted in an increase or loss of affinity.  
The following observations were made for the Lipinski 
rules13 compliant molecules constructed from the seed of 
3,3’,4’,5-tetrahydroxystilbene: 
 
1. Molecule number 16 (Fig. 14) had the highest affinity 
(pKd 9.97) within family number 2. A carboxyl group, at 
the locus encircled in Figure 15, took part in hydrogen 
bonding with Tyr341 and Arg106, and also formed an 
electrostatic interaction with Arg106 (Fig. 16). At this locus 
in molecule number 89 (Fig.17), which had the lowest 
affinity (pKd 9.74) within the family, two aromatic rings 
were instead present and no hydrogen bonding or 
electrostatic interactions with Tyr341 and Arg106 were 
formed (Fig.18).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14. Structure of molecule number 16, generated using 
Accelrys Discovery Studio® v.4.08 
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Figure 15. Pharmacophore of family number 2, generated 
using Accelrys Discovery Studio® v.4.08. The locus at which 
differences in moieties may have resulted in differences in 
affinity is encircled in green 
 
 
 
Figure 16.  Interactions of molecule number 16 within LBP 
of COX-2, generated using PoseView15. The interactions with 
Arg106 and Tyr341are encircled in red. 
 
 
 
 
 
 
 
 
 
Figure 17. Structure of molecule number 89, generated using 
Accelrys Discovery Studio® v.4.08. 
 
 
 
 
Figure 18. Interactions of molecule number 89 within LBP 
of COX-2, generated using PoseView15 
 
2. Molecule number 185 (Fig. 19) had the highest affinity 
(pKd 9.85) within family number 10. In molecule 
number 185, an amide moiety originated from the locus 
encircled in Figure 20, but was absent in molecule 
number 190 (Fig. 21), which had the lowest affinity 
(pKd 9.75) within this family. The amide moiety formed 
a hydrogen bond with Met508 (Fig.22). Molecule number 
190 did not form a hydrogen bond with Met (Fig. 23). 
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Figure 19. Structure of molecule number 185, generated 
using Accelrys Discovery Studio® v.4.08 
 
 
 
Figure 20. Pharmacophore of family number 10, generated 
using Accelrys Discovery Studio® v.4.08. The locus at which 
differences in moieties may have resulted in differences in 
affinity is encircled in green 
 
 
 
Figure 21. Structure of molecule number 190, generated 
using Accelrys Discovery Studio® v.4.08 
 
 
 
 
 
 
Figure 22. Interactions of molecule number 185 within LBP 
of COX-2, generated using PoseView15. The hydrogen bond 
with Met508 is encircled in red 
 
 
 
 
 
 
Figure 23. Interactions of molecule number 190 within LBP 
of COX-2, generated using PoseView15 
 
 
 
 
For the Lipinski Rules13 compliant molecules 
derived from the seed of 3,3’,4,4’,5,5’-hexahydroxystilbene, 
the following was determined: 
 
1. In molecule number 26 (Fig. 24), which had the highest 
affinity (pKd 9.84) in family number 1, an aromatic ring 
was present at the locus encircled in Figure 25. This ring 
was absent in molecule number 45 (Fig. 26) which had 
the lowest affinity (pKd 9.71) in this family. The 
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aromatic ring could be the reason as to why molecule 
number 26 made hydrophobic contact with another 
amino acid, namely Ser339, compared to molecule 
number 45 (Figs. 27-28). 
 
Figure 24. Structure of molecule number 26, generated using 
Accelrys Discovery Studio® v.4.08 
 
 
 
 
 
Figure 25. Pharmacophore of family number 1, generated 
using Accelrys Discovery Studio® v.4.08. The locus at which 
differences in moieties may have resulted in differences in 
affinity is encircled in green 
 
 
 
 
 
 
 
 
 
Figure 26. Structure of molecule number 45, generated using 
Accelrys Discovery Studio® v.4.08 
 
 
 
 
 
 
Figure 27. Interactions of molecule number 26 within LBP 
of COX-2, generated using PoseView15 
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Figure 28. Interactions of molecule number 45 within LBP 
of COX-2, generated using PoseView15 
 
 
 
 
 
2. For family number 9, molecule number 169 (Fig. 29) had 
the highest affinity (pKd 9.82), and molecule number 173 
(Fig. 30) had the lowest affinity (pKd 9.73). Both molecules 
had an aromatic ring at the locus encircled in Figure 31.  In 
molecule number 169, the side chain of the ring consisted of 
an ethyl group, whilst in molecule number 173 it comprised 
an aldehyde moiety. The ethyl group may have resulted in 
molecule number 169 being involved in two more 
hydrophobic interactions, namely with Tyr341 and Leu345, 
than molecule number 173 (Figs. 32-33). 
 
Figure 29. Structure of molecule number 169, generated 
using Accelrys Discovery Studio® v.4.08 
 
 
Figure 30. Structure of molecule number 173, generated 
using Accelrys Discovery Studio® v.4.08 
 
 
 
 
Figure 31. Pharmacophore of family number 9, generated 
using Accelrys Discovery Studio® v.4.08. The locus at which 
differences in moieties may have resulted in differences in 
affinity is encircled in green 
 
 
 
Figure 32. Interactions of molecule number 169 within LBP 
of COX-2, generated using PoseView15 
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Figure 33. Interactions of molecule number 173 within LBP 
of COX-2, generated using PoseView15 
 
 
 
Conclusion: 
This study identified novel in silico generated 
selective COX-2 inhibitors which have both high LBA (pKd) 
for the COX-2 receptor, and which, being Lipinski Rules13 
compliant, are orally bioavailable. These can be included in 
libraries of molecules which selectively inhibit COX-2 to be 
used in high-throughput screening. 
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